SCHEMBL1715419

SCHEMBL1715419

NOCCCNS(=O)(=O)Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.66
HPGD P15428 1/20 0.66
IDO1 P14902 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP8 P22894 1/20 0.49
MMP13 P45452 1/20 0.49
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.44
CYP19A1 P11511 1/20 0.43
PGR P06401 1/20 0.43
AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715342 0.90 ALDH1A1 (0.56) ALDH1A1HPGDIDO1MEN1KMT2A
SCHEMBL4601571 0.83 ALDH1A1 (0.70) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL9308055 0.81 ALDH1A1 (0.81) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL4441361 0.80 ALDH1A1 (0.65) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL28028789 0.79 MEN1 (0.69) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL6260651 0.78 ALDH1A1 (0.59) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL1716129 0.78 MAPK1 (0.71) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL7717614 0.78 ALDH1A1 (0.55) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL18986176 0.78 ALDH1A1 (0.58) ALDH1A1HPGDMEN1KMT2ACA1
SCHEMBL6261913 0.77 CA1 (0.58) ALDH1A1HPGDMEN1KMT2ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 ALDH1A1 804/4885HPGD 301/4885IDO1 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.